• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Klebsiella Infections - Pipeline Review, H2 2012 Product Image

Klebsiella Infections - Pipeline Review, H2 2012

  • ID: 2244974
  • September 2012
  • 41 pages
  • Global Markets Direct

Klebsiella Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Klebsiella Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Klebsiella Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Klebsiella Infections. Klebsiella Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Klebsiella Infections.
- A review of the Klebsiella Infections products under development by companies READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Klebsiella Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Klebsiella Infections 7
Klebsiella Infections Therapeutics under Development by Companies 9
Early Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Klebsiella Infections Therapeutics – Products under Development by Companies 13
Companies Involved in Klebsiella Infections Therapeutics Development 14
AlphaRx, Inc. 14
Rib-X Pharmaceuticals, Inc. 15
Orchid Chemicals & Pharmaceuticals Ltd 16
Achaogen Inc. 17
Phico Therapeutics Ltd. 18
Cantab Biopharmaceuticals Limited 19
Klebsiella Infections – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
plazomicin - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ciprofloxacin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RX-04 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SLP-0907 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 30
SASPject PT3.X - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
OCID5090 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Gram-Negative Programme - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Snare Antibacterial For Gram Negative Infections - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Klebsiella Infections Therapeutics – Drug Profile Updates 35
Klebsiella Infections Therapeutics - Dormant Products 37
Klebsiella Infections – Product Development Milestones 38
Featured News & Press Releases 38
Jan 06, 2011: NovaBay Reports Activity Of NVC-422 Against Deadly Superbug Producing NDM-1 38
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products Under Development for Klebsiella Infections, H2 2012 7
Products under Development for Klebsiella Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
AlphaRx, Inc., H2 2012 14
Rib-X Pharmaceuticals, Inc., H2 2012 15
Orchid Chemicals & Pharmaceuticals Ltd, H2 2012 16
Achaogen Inc., H2 2012 17
Phico Therapeutics Ltd., H2 2012 18
Cantab Biopharmaceuticals Limited, H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Klebsiella Infections Therapeutics – Drug Profile Updates 35
Klebsiella Infections Therapeutics – Dormant Products 37

List of Figures
Number of Products under Development for Klebsiella Infections, H2 2012 7
Products under Development for Klebsiella Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Early Clinical Stage Products, H2 2012 11
Discovery and Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos